Showing results (1-10 of 199) with videos related to
Sort By:
Pageof 20
Gynakologisch-Geburtshilfliche Rundschau|November 17, 1998
[Hormones and cancer: risk-benefit]P Sevelda, H SalzerArchives of Gynecology and Obstetrics|January 1, 1989
The value of second-look operation in patients with advanced epithelial ovarian carcinomaP Sevelda, C Dittrich, H SalzerGynecologic Oncology|December 1, 1989
Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinomaP Sevelda, C Dittrich, H SalzerOnkologie|December 1, 1985
[Results of the 1st Austrian ovarian cancer study: prospective randomized comparison of a new sequential chemotherapy with 2 standard regimens in 150 stage III and IV patients]P Sevelda, H Salzer, E Gitsch, et al.Geburtshilfe Und Frauenheilkunde|November 1, 1985
[Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers]P Sevelda, H Salzer, C Dittrich, et al.Cancer|May 15, 1990
Prognostic factors for survival in stage I epithelial ovarian carcinomaP Sevelda, N Vavra, M Schemper, et al.European Journal of Gynaecological Oncology|January 1, 1990
First experiences with intraperitoneal chemotherapy in ovarian cancerE Gitsch, P Sevelda, S Schmidl, et al.Cancer Chemotherapy and Pharmacology|January 1, 1990
The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study GroupK Karrer, H Salzer, P Sevelda, et al.Cancer Detection and Prevention|January 1, 1986
Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125P Sevelda, C Dittrich, H Salzer, et al.Geburtshilfe Und Frauenheilkunde|February 1, 1986
[Labor induction with 3 mg of prostaglandin E2 vaginal tablets. A renaissance of programmed labor? Results of a prospective randomized study]P Husslein, C Egarter, P Sevelda, et al.Pageof 20